Vivesto AB (STO:VIVE)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.0818
+0.0034 (4.34%)
Apr 14, 2026, 5:29 PM CET
Market Cap90.56M -29.7%
Revenue (ttm)n/a
Net Income-34.08M
EPS-0.06
Shares Out1.11B
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,217,882
Average Volume966,813
Open0.0798
Previous Close0.0784
Day's Range0.0774 - 0.0818
52-Week Range0.0700 - 0.3190
Beta0.82
RSI50.52
Earnings DateMay 13, 2026

About Vivesto AB

Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also offers Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixil, a drug candidate for the treatment of advanced cancer, and Docetaxel micellar for the treatment of prostate cancer. The company was formerly known a... [Read more]

Sector Healthcare
Founded 1988
Employees 4
Stock Exchange Nasdaq Stockholm
Ticker Symbol VIVE
Full Company Profile

Financial Performance

Financial Statements